AstraZeneca Plc $AZN, one of the leading pharmaceutical companies worldwide, has lost its status as the most valuable company listed on the London Stock Exchange. This event is a direct consequence of the stock market's reaction to changes proposed by the administration of U.S. President Donald Trump regarding drug price reductions.

Pharmaceutical giant AstraZeneca $AZN.L has reaffirmed its 2025 sales outlook, signaling confidence in its long-term strategy even amid potential disruptions from looming U.S. tariffs on EU-manufactured drugs. CEO Pascal Soriot stated that the forecast remains intact—provided any new tariffs imposed by Washington align with those already applied across other sectors.